Czyz Agata, Stillmock Kara A, Hazuda Daria J, Reznikoff William S
Department of Biochemistry, University of Wisconsin, 433 Babcock Drive, Madison, Wisconsin 53706, USA.
Biochemistry. 2007 Sep 25;46(38):10776-89. doi: 10.1021/bi7006542. Epub 2007 Aug 29.
Diketoacid (DKA) compounds have been shown to inhibit HIV-1 integrase by a mechanism that involves sequestration of the active site metals. Because HIV-1 integrase and Tn5 transposase have similar active site architectures and catalytic mechanisms, we investigated whether DKA analogues would inhibit Tn5 transposase activity and provide a model system to explore the mechanisms of action of these inhibitors. A screen of several hundred DKA analogues identified several with activity against Tn5 Tnp. Six DKA inhibitors used in this study manifested a variety of effects on different transposition steps suggesting that different analogues may have different binding contacts with transposase. All DKA compounds inhibited paired end complex (PEC) formation in which the nucleoprotein complex required for catalysis is assembled. Dissociation of PECs by some DKA compounds indicates that these inhibitors can decrease PEC stability. Four DKA compounds inhibited the two cleavage steps releasing transposon DNA from flanking DNA, and one of these four compounds preferentially inhibited the second cleavage step. The differential effect of this inhibitor on the second cleavage event indicates that cleavage of the two transposon-donor DNA boundaries is a sequential process requiring a conformational change. The requirement for a conformational change between cleavage events was also demonstrated by the inability of transposase to perform second cleavage at 25 degrees C. Finally, all six compounds inhibit strand transfer, the final step of Tn5 transposition. Two of the compounds that inhibited strand transfer have no effect on DNA cleavage. The strand transfer inhibition properties of various DKA compounds was sensitive to the structure of the 5'-non-transferred strand, suggesting that these compounds bind in or near the transposase active site. Other results that probe compound binding sites include the effects of active site mutations and donor DNA on DKA compound inhibition activities. Thus, DKA inhibitors will provide an important set of tools to investigate the mechanism of action of transposases and integrases.
二酮酸(DKA)化合物已被证明可通过一种涉及隔离活性位点金属的机制来抑制HIV-1整合酶。由于HIV-1整合酶和Tn5转座酶具有相似的活性位点结构和催化机制,我们研究了DKA类似物是否会抑制Tn5转座酶活性,并提供一个模型系统来探索这些抑制剂的作用机制。对数百种DKA类似物的筛选鉴定出了几种对Tn5 Tnp有活性的类似物。本研究中使用的六种DKA抑制剂对不同的转座步骤表现出多种影响,这表明不同的类似物可能与转座酶有不同的结合接触。所有DKA化合物均抑制配对末端复合物(PEC)的形成,催化所需的核蛋白复合物在此过程中组装。一些DKA化合物导致PEC解离,这表明这些抑制剂可降低PEC的稳定性。四种DKA化合物抑制从侧翼DNA释放转座子DNA的两个切割步骤,这四种化合物中的一种优先抑制第二个切割步骤。这种抑制剂对第二个切割事件的不同影响表明,两个转座子-供体DNA边界的切割是一个需要构象变化的连续过程。转座酶在25摄氏度下无法进行第二次切割也证明了切割事件之间对构象变化的需求。最后,所有六种化合物均抑制链转移,这是Tn5转座的最后一步。两种抑制链转移的化合物对DNA切割没有影响。各种DKA化合物的链转移抑制特性对5'-未转移链的结构敏感,这表明这些化合物在转座酶活性位点内或附近结合。其他探究化合物结合位点的结果包括活性位点突变和供体DNA对DKA化合物抑制活性的影响。因此,DKA抑制剂将提供一组重要的工具来研究转座酶和整合酶的作用机制。